In the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG.
David Loew, formerly executive vice president of Sanofi Pasteur, was appointed as CEO of French Ipsen Pharma SA at the beginning of July.
Emperor Nero, reportedly, fiddled as Rome burned in 64 A.D., much like society for a long time ignored and repressed the pending crisis of antimicrobial resistance (AMR).
AbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats.
Evox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases.
Swedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.
Dr Savita Bernal joined the Lyon-based MaaT Pharma as new Chief Business Officer.
Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
NodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
An analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.